盐酸达泊西汀联合小剂量他达拉非治疗原发性早泄的前瞻性随机对照临床研究

邢增术; 张冲; 刘振湘; 白志明

doi:10.13201/j.issn.1001-1420.2018.08.008

盐酸达泊西汀联合小剂量他达拉非治疗原发性早泄的前瞻性随机对照临床研究

- 中南大学湘雅医学院附属海口医院泌尿外科 (海口, 570208)

详细信息

通讯作者: 邢增术,E-mail:xingzengshu2006@126.com

中图分类号: R698

收稿日期: 2018-05-21

Prospective randomized controlled trial on treatment of primary premature ejaculation with dapoxetine hydrochloride and tadalafil

- Department of Urology, Haikou Hospital Affiliated to Xiangya School of Medicine, Central South University, Haikou, 570208, China

More Information

Corresponding author: XING Zengshu, E-mail: xingzengshu2006@126.com

Received Date: 21 May 2018

摘要

摘要: 目的:评价盐酸达泊西汀联合小剂量他达拉非治疗原发性早泄(PE)的临床疗效。方法:收集原发性PE患者97例,随机分成对照组(n=46)和治疗组(n=51),对照组性交前按需口服盐酸达泊西汀30mg;治疗组性交前按需口服盐酸达泊西汀片30mg,同时每日服用(OAD)小剂量他达拉非片5mg,疗程12周。嘱患者在治疗期间规律性生活,每月性生活≥4次,治疗前后行中国早泄患者性功能评价表5(CIPE-5)评分及阴道内射精潜伏期(IELT)测评并做好相关记录。结果:与治疗前比较,治疗后两组CIPE-5评分及IELT均明显提高,差异有统计学意义(P<0.05)。与对照组比较,治疗后治疗组的CIPE-5评分及IELT改善更为明显,差异有统计学意义(P<0.05)。两组患者治疗期间不良事件发生率差异无统计学意义(P>0.05),不良事件可自行缓解。结论:盐酸达泊西汀联合小剂量他达拉非治疗原发性PE安全有效。
- 原发性早泄 /
- 盐酸达泊西汀 /
- 他达拉非
Abstract: Objective:To assess the clinical efficacy of dapoxetine hydrochloride combined with tadalafil at low dosage in the treatment of primary premature ejaculation.Method:Ninety-seven male outpatients with primary premature ejaculation were divided randomly into 2 groups.The control group (46 cases) was only treated with on-demand 30 mg dapoxetine hydrochloride orally before sexual intercourse.The treatment group (51 cases) was treated with dapoxetine hydrochloride in the same way and 5 mg tadalafil orally once a day.All treatments were given for 12 weeks.During the treatment, the patients were required for regular sex no less than 4 times a month, and to make records for CIPE-5 scores and IELT before and after treatment.Result:In both groups, CIPE-5 scores and IELT were improved significantly after treatment (P<0.05).However, CIPE-5 scores and IELT of the treatment group were improved more significantly than those of the control group (P<0.05).There was no statistical difference in incidence of adverse events between two groups (P>0.05), and all of adverse events could be relieved by themselves.Conclusion:The treatment of dapoxetine hydrochloride combined with tadalafil at low dosage is safe and effective for primary premature ejaculation.
- primary premature ejaculation /
- dapoxetine hydrochloride /
- tadalafil

HTML全文

参考文献(13)

[1]	Saitz T R, Serefoglu E C.The epidemiology of premature ejaculation[J].Transl Androl Urol, 2016, 5 (4):409-415.
[2]	Hatzimouratidis K, Giuliano F, Moncada I, et al.EAU male sexual dysfunction guidelines for premature ejaculation (version 1.2018)[OL].http://uroweb.org/guideline/male-sexual-dysfunction/.
[3]	袁亦铭, 辛钟成, 金泰乙, 等.中国早泄患者性功能评价表对早泄患者的多维评估[J].中国男科学杂志, 2003, 17 (5):302-306.
[4]	Althof S E, McMahon C G, Waldinger M D, et al.An update of the International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation[J].J Sex Med, 2014, 11 (6):1392-1422.
[5]	Shabsigh R.Diagnosing premature ejaculation:A review[J].J Sex Med, 2006, 3 Suppl 4:318-323.
[6]	Hatzimouratidis K, Amar E, Eardley I, et al.Guidelines male sexual dysfunction:Erectile dysfunction and premature ejaculation[J].Eur Urol, 2010, 57 (5):804-814.
[7]	Giuliano F.5-Hydroxytryptamine in premature ejaculation:opportunities for therapeutic intervention[J].Trends Neurosci, 2007, 30 (2):79-84.
[8]	Martyn-St James M, Cooper K, Ren S, et al.Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation:A Systematic Review and Meta-analysis[J].Eur Urol Focus, 2017, 3 (1):119-129.
[9]	Aversa A, Francomano D, Bruzziches R, et al.Is there a role for phosphodiesterase type-5inhibitors in the treatment of premature ejaculation?[J].Int J Impot Res, 2011, 23 (1):17-23.
[10]	Martyn-St James M, Cooper K, Ren S, et al.Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation:A Systematic Review and Meta-analysis[J].Eur Urol Focus, 2017, 3 (1):119-129.
[11]	Jiann B R, Huang Y J.Assessing satisfaction in men with premature ejaculation after dapoxetine treatment in real-world practice[J].Int J Clin Pract, 2015, 69 (11):1326-1333.
[12]	Abu EI-Hamd M, Abdelhamed A.Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation:A randomised placebo-controlled clinical trial[J].Andrologia, 2018.
[13]	Bai Y, Pu C, Han P, et al.Selective Serotonin Reuptake Inhibitors Plus Phosphodierase-5 Inhibitors for Premature Ejaculation:A Systematic Review and Meta-analysis[J].Urology, 2015, 86 (4):758-764.